Authors:
Somlo, G
Chow, W
Hamasaki, V
Leong, L
Margolin, K
Morgan, R
Sniecinski, I
Frankel, P
Reardon, D
Longmate, J
Raschko, J
Shibata, S
O'Donnell, M
Smith, E
Tetef, M
Forman, S
Yen, Y
Molina, A
Doroshow, JH
Citation: G. Somlo et al., Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies, BIOL BLOOD, 7(5), 2001, pp. 284-293
Authors:
Tetef, ML
Synold, TW
Chow, W
Leong, L
Margolin, K
Morgan, R
Raschko, J
Shibata, S
Somlo, G
Yen, Y
Groshen, S
Johnson, K
Lenz, HJ
Gandara, D
Doroshow, JH
Citation: Ml. Tetef et al., Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies, CLIN CANC R, 7(6), 2001, pp. 1569-1576
Authors:
Morgan, RJ
Synold, T
Carr, BI
Doroshow, JH
Womack, EP
Shibata, S
Somlo, G
Raschko, J
Leong, L
McNamara, M
Chow, W
Tetef, M
Margolin, K
Akman, S
Longmate, J
Citation: Rj. Morgan et al., Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy, CANC CHEMOT, 47(4), 2001, pp. 327-332
Citation: J. Legaspi et al., Talectomy in patients with recurrent deformity in club foot - A long-term follow-up study, J BONE-BR V, 83B(3), 2001, pp. 384-387
Authors:
Morgan, RJ
Doroshow, JH
Leong, L
Schriber, J
Shibata, S
Forman, S
Hamasaki, V
Margolin, K
Somlo, G
Alvarnas, J
McNamara, M
Longmate, J
Raschko, J
Chow, W
Vasilev, S
McGonigle, K
Yen, Y
Citation: Rj. Morgan et al., Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer, BONE MAR TR, 28(9), 2001, pp. 859-863
Authors:
Somlo, G
Doroshow, JH
Synold, T
Longmate, J
Reardon, D
Chow, W
Forman, SJ
Leong, LA
Margolin, KA
Morgan, RJ
Raschko, JW
Shibata, SI
Tetef, ML
Yen, Y
Kogut, N
Schriber, J
Alvarnas, J
Citation: G. Somlo et al., High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome, BR J CANC, 84(12), 2001, pp. 1591-1598
Authors:
Raschko, JW
Synold, TW
Chow, W
Coluzzi, P
Hamasaki, V
Leong, LA
Margolin, KA
Morgan, RJ
Shibata, SI
Somlo, G
Tetef, ML
Yen, Y
ter Veer, A
Doroshow, JH
Citation: Jw. Raschko et al., A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A, CANC CHEMOT, 46(5), 2000, pp. 403-410
Authors:
Tetef, M
Leong, L
Ahn, C
Akman, S
Chow, W
Margolin, K
Morgan, RJ
Raschko, J
Shibata, S
Somlo, G
Doroshow, JH
Citation: M. Tetef et al., Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial, CANCER INV, 17(2), 1999, pp. 114-117
Citation: W. Chow et al., Microscopic theory of optical nonlinearities and spontaneous emission lifetime in group-III nitride quantum wells, PHYS REV B, 60(3), 1999, pp. 1947-1952
Authors:
Somlo, G
Sniecinski, I
ter Veer, A
Longmate, J
Knutson, G
Vuk-Pavlovic, S
Bhatia, R
Chow, W
Leong, L
Morgan, R
Margolin, K
Raschko, J
Shibata, S
Tetef, M
Yen, Y
Forman, S
Jones, D
Ashby, M
Fyfe, G
Hellmann, S
Doroshow, JH
Citation: G. Somlo et al., Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy, BLOOD, 93(9), 1999, pp. 2798-2806